Alpha Cognition Inc.

ACOG · Nasdaq · Canada / United States

Share price · ACOG

$8.60+0.03 (+0.29%) 3M

close as of 2026-11-18 · 24h delayed · vol 282K (2.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ACOG's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026+8.6%
  2. 20 Aug 2026+6.9%

    Nothing announced by ACOG that day or the session before.

  3. 27 Jul 2026+8.6%
  4. 21 Jul 2026-5.4%

    Nothing announced by ACOG that day or the session before.

  5. 1 Jul 2026+7.9%

    Nothing announced by ACOG that day or the session before.

  6. 17 Jun 2026+11.1%

    Nothing announced by ACOG that day or the session before.

  7. 15 May 2026+6.0%
  8. 12 May 2026-7.7%

    Nothing announced by ACOG that day or the session before.

  9. 7 Apr 2026+12.3%

    Nothing announced by ACOG that day or the session before.

  10. 18 Feb 2026+11.3%

    Nothing announced by ACOG that day or the session before.

Share of unusual movement by asset

For each asset, the share of ACOG's own-move activity since 13 Nov 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Benzgalantamine (Zunveyl)
events and moves
5shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—4%
Sessions with no dated event—96%

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Approved
Acetylcholinesterase/nicotinic receptor (prodrug)Small molecule
Alzheimer's Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (11)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$7.8M$1.3M$38M$7.6M-$4.8M operating cash flowreport ↗
View 10 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$6.1M$2.0M$41M$8.8M-$6.9M operating cash flowreport ↗
2026-Q1$3.5M$1.1M$54M$6.5M-$12M operating cash flowreport ↗
2025-Q3$2.8M$0.6M$35M$1.3M-$5.3M operating cash flowreport ↗
2025-Q2$1.7M$0.3M$39M$10M-$6.1M operating cash flowreport ↗
2025-Q1$2.9M$0.4M$46M$2.0M-$2.0M operating cash flowreport ↗
2024-Q3—$1.0M$3.8M$1.9M-$1.6M operating cash flowreport ↗
2024-Q2—$1.0M$1.2M$2.1M-$1.4M operating cash flowreport ↗
2024-Q1—$0.9M$2.4M$5.0M-$2.5M operating cash flowreport ↗
2023-Q3—$1.4M$0.9M$3.3M-$1.6M operating cash flowreport ↗
2023-Q2—$1.3M$1.2M$2.8Mreport ↗

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$10M$1.9M$66M$5.2M-$20M operating cash flowreport ↗

Alpha Cognition reported fiscal 2025 total revenue of $10.22M, consisting of $6.8M in ZUNVEYL net product revenue and $3.4M in licensing revenue. R&D spend was $1.87M, down 52.3% YoY from $3.92M, and cash and cash equivalents totaled $66.11M at year-end. The company reported a net loss of $20.67M, with quarterly net burn of $20.67M.

Management reiterated its target of operating profitability in 2027 and expects approximately two years of cash runway at forecasted operating levels. The company executed a second national PBM contract, bringing it to two of four major PBMs relevant to long-term care, and fourth-quarter bottles dispensed rose 62% QoQ to 4,941, with December the strongest month since launch. Operational highlights include ongoing enrollment in the BEACON study, planned initiation of the CONVERGE and RESOLVE studies, planned advancement of a sublingual formulation into the clinic in 2026, expected ex-US approvals via partner CMS in Asia, and issuance of an additional U.S. patent covering ZUNVEYL dosing regimens.

View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$3.9M$49M$3.7M-$7.8M operating cash flowreport ↗
2023-FY—$4.9M$1.5M$3.4M-$8.8M operating cash flowreport ↗
2022-FY——$2.1M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 60 purchases ($8.3M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-11Deardorf Caren · directorAward / grant755——Form 4
2026-11-11Deardorf Caren · directorAward / grant (derivative)1,020——Form 4
2026-10-23Opaleye Management Inc. · 10% ownerOpen-market purchase14,973$8.23$123KForm 4
2026-10-22Opaleye Management Inc. · 10% ownerOpen-market purchase17,117$8.33$143KForm 4
2026-10-16Opaleye Management Inc. · 10% ownerOpen-market purchase14,283$8.23$118KForm 4
2026-10-15Opaleye Management Inc. · 10% ownerOpen-market purchase22,657$8.43$191KForm 4
2026-10-01Opaleye Management Inc. · 10% ownerOpen-market purchase19,050$8.69$166KForm 4
2026-09-25Opaleye Management Inc. · 10% ownerOpen-market purchase13,426$8.47$114KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 24 reporting institutions held 10.5M shares ($57.7M, 48.3% of shares outstanding).

#InstitutionSharesValue
1Opaleye Management Inc.2,561,950$14.1M
2Solas Capital Management, LLC1,924,617$10.6M
3AWM Investment Company, Inc.1,672,168$9.2M
4Cable Car Capital, LP1,382,339$7.6M
5Ikarian Capital, LLC1,056,259$5.8M
6SPHERA FUNDS MANAGEMENT LTD.567,616$3.1M
7Alyeska Investment Group, L.P.365,000$2.0M
8BOOTHBAY FUND MANAGEMENT, LLC256,393$1.4M
9Aristides Capital LLC218,510$1.2M
10CANTOR FITZGERALD, L. P.188,631$1.0M
11CITADEL ADVISORS LLC89,589$492K
12VILLERE ST DENIS J & CO LLC71,158$391K
13TUDOR INVESTMENT CORP ET AL61,596$338K
14ACT CAPITAL MANAGEMENT, LLC51,500$283K
15TWO SIGMA INVESTMENTS, LP15,886$87K